Cargando…

A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma

Esophageal small cell carcinoma (E-SmCC) and basaloid squamous cell carcinomas (BSCCs) are both highly aggressive malignancies, but their detailed differences in clinical behaviors have remained virtually unknown. In addition, treatment strategies of the patients with E-SmCC have not been establishe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Hirotaka, Kasajima, Atsuko, Onodera, Yu, Konno, Takuro, Maruyama, Shota, Okamoto, Hiroshi, Sato, Chiaki, Heishi, Takahiro, Sakurai, Tadashi, Taniyama, Yusuke, Takahashi, Masanobu, Fujishima, Fumiyoshi, Jingu, Keiichi, Ishioka, Chikashi, Sasano, Hironobu, Kamei, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408094/
https://www.ncbi.nlm.nih.gov/pubmed/30813135
http://dx.doi.org/10.1097/MD.0000000000014363
Descripción
Sumario:Esophageal small cell carcinoma (E-SmCC) and basaloid squamous cell carcinomas (BSCCs) are both highly aggressive malignancies, but their detailed differences in clinical behaviors have remained virtually unknown. In addition, treatment strategies of the patients with E-SmCC have not been established. 29 cases of E-SmCC and 39 with BSCC were examined in this study to clarify the clinical features and outcome of the patients with E-SmCC and to compare the findings with those of BSCC. E-SmCCs presented a more advanced status than BSCC (TNM Stage: P = .002). Esophagectomy was performed in 15 small cell carcinoma patients and 14 were treated with non-surgical/systemic therapy. The clinical outcome of the small cell carcinoma cases was significantly worse than those with BSCC (P = .001), but results of a stage-stratified analysis revealed that the Stage I small cell carcinoma patients presented favorable prognosis (3-year survival rate 100%, n = 4). In contrast, among those with Stage II–IV, clinical outcome tended to be better in the systemic therapy group (3-year survival rate 49%, n = 13) than the surgically treated group (3-year survival rate 0%, n = 12). E-SmCC was a more aggressive neoplasm than BSCC. However, early detection could possibly improve the clinical outcome of patients with E-SmCC. Systemic therapy could also benefit the patients with advanced disease (Stage II–IV).